New weight loss drug shows promise in Long-Term Follow-Up study

NCT ID NCT06671821

Completed Disease control Sponsor: Shandong Suncadia Medicine Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at the long-term safety and effectiveness of the drug HRS-7535 for weight management in 81 adults with obesity who had already completed a 36-week treatment course. Participants took the drug for an additional 32 weeks to see how well it helped maintain weight loss and whether any side effects appeared. The goal is to see if HRS-7535 can be a safe and effective long-term option for managing obesity.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HRS-7535 (a drug tablet for weight loss)
What this could lead to: If successful, this could support HRS-7535 as a long-term weight management option for obesity, potentially helping people achieve and maintain significant weight loss.
What could go wrong: This is a small, completed Phase 2 extension study with only 81 participants. Long-term safety and efficacy are still being evaluated, and results may not apply to all people with obesity.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC WEIGHT MANAGEMENT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

obesity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC WEIGHT MANAGEMENT

Contacts and locations

Locations

Chinese PLA General Hospital

Beijing, Beijing Municipality, 100039, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.